There is a new passive vaccination for RSV in infants called Beyfortus (nirsevimab). RSV or respiratory syncytial virus is an infection that causes infants to develop fever, feel ill, wheeze, and have difficulty breathing. Each year between 80,000 and 100,000 children are hospitalized because of RSV infection; 100-300 child die annually from the disease.
Beyfortus is a long acting, monoclonal antibody that is available for all children under 8 months of age both during and entering their first RSV season (fall through spring). The injection can also be given to select children during and entering their second RSV season (up to age 2 years).
The immunization is expensive, but most insurances now cover the cost. The vaccine is very effective, reducing the likelihood by up to 80% that a child will not be hospitalized by RSV. Immunization is also safe with very few reported side effects.
There are other ways to prevent RSV infection. A vaccine called Abrysvo is available to pregnant moms during the third trimester. While it has some side effects, it has been shown to be up to 50% effective at reducing RSV admissions in infants. The same reduction in hospital admissions has been shown among infants who breast feed - the easiest, least expensive, and safest option of all.
The Pediatric Group now has Beyfortus. Call to speak to a practitioner or set up an appointment to get your child immunized.
